OlympiA phase III trial of Lynparza for the treatment of BRCA-mutated high-risk HER2-negative early breast cancer will reported early – AstraZeneca + Merck Inc
The OlympiA Phase III trial for AstraZeneca and MSD’s Lynparza will move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).
